Trial Profile
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Ropinirole (Primary)
- Indications Restless legs syndrome
- Focus Adverse reactions; Registrational
- Sponsors GlaxoSmithKline; GSK
- 18 May 2019 Trial has been completed in UK.
- 02 Nov 2012 Planned number of patients changed from 480 to 488 as reported by European Clinical Trials Database.
- 02 Nov 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2005-000184-25).